Intarcia snags $200M for yearlong diabetes minipump in PhIII; Alnylam gets orphan status positive opinion in Europe;

> Intarcia pulled in $200 million for its Phase III exenatide minipump designed to deliver the drug to diabetes patients over the course of a year. Story

> The European Medicines Agency gave Alnylam ($ALNY) a positive opinion regarding the orphan status of the company's ALN-TTRsc RNAi drug for patients with transthyretin-mediated amyloidosis. Release

> Particle Sciences entered a development agreement with Actavis ($ACT) for an unnamed generic product using one of Particle's many delivery technologies. Release

> Ablative Solutions won FDA clearance for its Peregrine infusion catheter designed to deliver drugs directly to the perivascular layer surrounding the blood vessels. Release

> Biolight filed an IND with the FDA for a Phase I/IIa study of its glaucoma implant with controlled release of latanaprost. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.